IND, NDA, and BLA
Building a Regulatory Roadmap for IND, NDA, and BLA
Rebecca Lamb-Wharton, Ph.D.; Brenda Schlenk, RPh; Mamadou Diallo, PharmD
PAO-03-24-CL-10Mar 26, 2024
Nice Insight API Report
Small Molecule API Discovery and Development Trends
April Stanley, MS MBA
Nice Insight
PAO-03-24-NI-01Mar 21, 2024
mRNA–LNP Manufacturing
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
Antonio Costa, Ph.D.; William Pasek
DIANT Pharma
PAO-03-24-CL-08Mar 18, 2024
Radioconjugate development
Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool
Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.
GBI
PAO-03-24-CL-07Mar 15, 2024
Viral Vectors
A Viral Vector CDMO Vision that Resonates
Drew Brennan; Chris Berger; Elie Hanania, Ph.D.; Dave Ingamells; Rami Barghout, PE
Avid Bioservices
PAO-03-24-CL-06Mar 14, 2024
Analytical Method Development
Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development
Xuemei Han, Ph.D.
Tanvex CDMO
PAO-03-24-CL-09Mar 13, 2024
Clinical Trials Representation
Leveraging Decentralized Clinical Trial Strategies to Reduce Health Care Disparities
Jennifer Urwongse
PPD clinical research business of Thermo Fisher Scientific
PAO-03-24-CL-05Mar 13, 2024
Commitment to ESG Principles
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Pharma's Almanac
PAO-03-24-CL-03Mar 08, 2024
Accelerating Product Development
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Pharma's Almanac
PAO-03-24-CL-02Mar 08, 2024
Bispecific Antibodies
Accelerating the Development and Production of High-Quality Bispecific Antibodies
Dongyoung Park
Samsung Biologics
PAO-03-24-CL-01Mar 04, 2024
Pediatric Clinical Trials
Pediatric Clinical Trials: Considerations for Enrollment and Retention
Susan McCune, M.D.; Anusha Streubel, M.D.; Elizabeth Donahue
PAO-02-24-CL-04Mar 01, 2024
Digital Pathology
Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform
Nathan Buchbinder
Proscia
PAO-01-24-CL-2Feb 29, 2024
Portable CMC
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
Wheeler Bio
PR-M02-29-01Feb 29, 2024
Advanceability
Right from the Start: Designing Advanceable Formulations and Processes at Phase I
Serán Bioscience
PAO-02-24-CL-09Feb 26, 2024
3D Printing
Exploring New Possibilities with 3D Printing of Pharmaceuticals
Thomas Kipping, Ph.D.
MilliporeSigma
PAO-02-24-CL-11Feb 23, 2024
CDMO - Small Biotech
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
Julie Trulson, Ph.D.
PAO-02-24-CL-07Feb 15, 2024
Tech Transfer
Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies
Julie Trulson, Ph.D.
PAO-02-24-CL-06Feb 15, 2024
Biologics Formulation
Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform
Pawel Stanczak, Ph.D.
Tanvex CDMO
PAO-02-24-CL-02Feb 15, 2024
Translation
The Translational Index Score: Improving the Entire Drug Development Cycle
Jo Varshney, Ph.D., D.V.M.
PAO-02-24-CL-10Feb 15, 2024
Cell-Free
Cell-Free Protein Synthesis Holds Real Potential to Transform Drug Development and Manufacturing
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-02-24-NI-01Feb 14, 2024